Ignite Creation Date:
2024-05-06 @ 9:18 AM
Last Modification Date:
2024-10-26 @ 12:12 PM
Study NCT ID:
NCT02953457
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-20
First Post:
2016-11-01
Brief Title:
Olaparib Durvalumab and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Sponsor:
Roswell Park Cancer Institute
Organization:
Roswell Park Cancer Institute
Organization Data
Organization:
Roswell Park Cancer Institute
Class:
OTHER
Study ID:
I 288216
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Roswell Park Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |